Physician profile
Melvin R Helm
NPI 1124076211
$203,409.70
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $77K · 2021: $67K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51,387.95 | 2019-2021 | |
| Lilly USA, LLC | $43,609.79 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $36,818.19 | 2019-2021 | |
| Abbvie INC. | $24,862.35 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22,814.53 | 2020-2021 | |
| Amgen INC. | $18,041.24 | 2019-2021 | |
| Lundbeck LLC | $2,556.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $551.80 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $300.20 | 2019-2021 | |
| Ucb, INC. | $290.17 | 2019-2021 | |
| Zyla Life Sciences, INC. | $286.01 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $268.75 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $266.48 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $254.05 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $245.70 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $180.02 | 2019 | |
| Assertio Therapeutics, INC. | $146.17 | 2020 | |
| Neuronetics, INC. | $117.14 | 2019-2020 | |
| Almatica Pharma LLC | $64.60 | 2021 | |
| Arbor Pharmaceuticals, INC. | $46.33 | 2019-2021 | |
| Acorda Therapeutics, INC | $45.06 | 2019-2020 | |
| Biogen, INC. | $40.74 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.56 | 2020 | |
| Akcea Therapeutics, INC. | $32.49 | 2019 | |
| Celgene Corporation | $27.32 | 2020-2021 | |
| Eisai INC. | $23.47 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.74 | 2021 | |
| Merck Sharp & Dohme LLC | $16.93 | 2019 | |
| Genentech USA, INC. | $16.00 | 2019 | |
| Sk Life Science, INC. | $14.50 | 2020 | |
| Neurocrine Biosciences, INC. | $14.30 | 2020 | |
| Pfizer INC. | $12.82 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$12,825.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Helm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.